metricas
covid
Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Colchicine in stroke prevention. Is it time to change our clinical practice?
Información de la revista
Vol. 38. Núm. 2.
Páginas 137-138 (marzo 2023)
Vol. 38. Núm. 2.
Páginas 137-138 (marzo 2023)
Letter to the Editor
Open Access
Colchicine in stroke prevention. Is it time to change our clinical practice?
Colchicina en prevención del ictus. ¿Es hora de cambiar nuestra práctica clínica?
Visitas
3456
L. Castilla-Guerraa,b,
Autor para correspondencia
lcastilla@us.es

Corresponding author.
, M.C. Fernandez-Morenob,c, M.D. Jiménez-Hernándezb,d, M.Á. Rico-Corrala,b
a Unidad de Riesgo Vascular, Servicio de Medicina Interna, Hospital Virgen Macarena, Sevilla, Spain
b Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain
c Servicio de Neurología, Hospital de Valme, Sevilla, Spain
d Servicio de Neurología, Hospital Virgen del Rocío, Sevilla, Spain
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
Dear Editor:

Colchicine is an old drug with several anti-inflammatory properties that has traditionally been used to treat various rheumatic disorders (for example, gout and Behçet disease, among others).1 Specifically, it prevents the development of microtubules by inhibiting leukocyte function, and blocks the assembly of the NOD-like receptor P3 (NLRP3) inflammasome, preventing the release of IL-1β and the expression of other proinflammatory cytokines, some of which are known to play a role in cerebrovascular disease, such as MMP-9.2,3

Colchicine is used similarly to statins in the prevention of ischaemic stroke. Thus, in the Scandinavian Simvastatin Survival Study (4S), the first randomised prospective trial of a statin, simvastatin not only decreased overall mortality (30%) and the frequency of coronary events (34%), but also the frequency of stroke (30%).4

It should be noted that all patients in the 4S trial presented coronary artery disease (CAD). Furthermore, the majority of trials addressing the secondary prevention of CAD (4S, CARE, LIPID, GREACE, and TNT) found statins to be beneficial in stroke prevention. Finally, in the SPARCL trial, the first trial of secondary stroke prevention in patients without CAD, atorvastatin significantly reduced stroke.5

In this regard, colchicine has emerged as a therapeutic option for the secondary prevention of cardiovascular disease in patients with CAD.

Over the past 3 decades, several observational and randomised studies have assessed the impact of colchicine in patients with CAD and shown a reduction in the frequency of ischaemic events, including revascularisation, myocardial infarction, and also stroke or transient ischaemic attack (TIA).2,3

Similarly, patients surviving ischaemic stroke present greater risk of new events, approximately 30% at 5 years, partly due to arterial inflammation,6 also known as residual inflammatory risk.7

Thus, therapies specifically aiming to treat the inflammatory risk may decrease the rate of recurrent events. In the paradigmatic CANTOS trial, inhibition of the NOD-like receptor protein 3 inflammasome using the anti–IL-1β monoclonal antibody canakinumab decreased the rate of cardiovascular events in patients with elevated high-sensitivity C-reactive protein test results, also showing a possible 30% reduction in the risk of stroke.7

In fact, in a recent prospective multicentre cohort study of 10 499 patients with ischaemic stroke or TIA, residual inflammatory risk (defined as presenting an LDL cholesterol level < 100mg/dL and high-sensitivity C-reactive protein level ≥ 3mg/L) was associated with recurrent stroke (hazard ratio, 1.18; 95% CI, 1.00-1.40).8

A systematic review and meta-analysis of randomised controlled trials showed that the decrease in severe cardiovascular events with colchicine was greatest for stroke, with reductions in risk of 62%, 44%, and 38% for ischaemic stroke, emergency coronary revascularisation, and myocardial infarction, respectively.2

Another recent meta-analysis of randomised controlled clinical trials including 6630 patients at high cardiovascular risk specifically analysed the role of colchicine in stroke prevention. The use of colchicine led to a significant reduction in the risk of stroke (odds ratio, 0.33; 95% CI, 0.15-0.70).9

Colchicine would reduce not only the growth of the plaque,2,3 but also the risk of atrial fibrillation,10 and even prevent both the progression of the peripheral vascular disease at the carotid level11 and the progression of aortic aneurysms, by inhibiting the degradation of the extracellular matrix.12

Several clinical trials are currently assessing the usefulness of colchicine in the prevention of vascular events after a stroke or TIA. Thus, the CONVINCE trial, which includes 3154 patients with non-cardioembolic stroke or high-risk TIA, aims to determine whether adding colchicine to the standard treatment leads to a reduction in the recurrence of stroke and vascular events.13

In the meantime, the 2021 guidelines of the European Society of Cardiology recommend for the first time the use of anti-inflammatory treatment for the secondary prevention of atherosclerosis. They recommend considering low-dosed colchicine (0.5mg once daily) for the secondary prevention of cardiovascular disease when other risk factors are not sufficiently controlled, or if recurrent events occur despite optimal treatment (grade of recommendation IIb, level of evidence I).14

Therefore, colchicine, a safe and frequently used anti-inflammatory drug that inhibits the inflammation associated with vascular disease, creates a new paradigm in the prevention of atherosclerotic ischaemic stroke. We may soon see a new change in our clinical practice.

References
[1]
G. Liantinioti, A.A. Argyris, A.D. Protogerou, P. Vlachoyiannopoulos.
The role of colchicine in the treatment of autoinflammatory diseases.
Curr Pharm Des, 24 (2018), pp. 690-694
[2]
M. Samuel, J.C. Tardif, N. Bouabdallaoui, P. Khairy, M.P. Dubé, L. Blondeau, et al.
Colchicine for secondary prevention of cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.
Can J Cardiol, 37 (2021), pp. 776-785
[3]
F. Condello, M. Sturla, B. Reimers, G. Liccardo, G.G. Stefanini, G. Condorelli, et al.
Association between colchicine treatment and clinical outcomes in patients with coronary artery disease: Systematic review and meta-analysis.
Eur Cardiol, 16 (2021), pp. e39
[4]
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[5]
L. Castilla-Guerra, M.D.C. Fernandez-Moreno, D. Leon-Jimenez, M.A. Rico-Corral.
Statins in ischemic stroke prevention: What have we learned in the post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) decade?.
Curr Treat Options Neurol, 21 (2019), pp. 22
[6]
M. Boulanger, Y. Béjot, P.M. Rothwell, E. Touzé.
Long-term risk of myocardial infarction compared to recurrent stroke after transient ischemic attack and ischemic stroke: Systematic review and meta-analysis.
J Am Heart Assoc, 7 (2018),
[7]
P.M. Ridker, B.M. Everett, T. Thuren, J.G. MacFadyen, W.H. Chang, C. Ballantyne, et al.
Antiinflammatory therapy with canakinumab for atherosclerotic disease.
N Engl J Med, 377 (2017), pp. 1119-1131
[8]
J. Li, Y. Pan, J. Xu, S. Li, M. Wang, K. Quan, et al.
Residual inflammatory risk predicts poor prognosis in acute ischemic stroke or transient ischemic attack patients.
Stroke, 52 (2021), pp. 2827-2836
[9]
W. Masson, M. Lobo, G. Molinero, G. Masson, A. Lavalle-Cobo.
Role of colchicine in stroke prevention: An updated meta-analysis.
J Stroke Cerebrovasc Dis, 29 (2020),
[10]
B. Varghese, D.I. Feldman, C. Chew, E. Valilis, R.S. Blumenthal, G. Sharma, H. Calkins.
Inflammation, atrial fibrillation, and the potential role for colchicine therapy.
Heart Rhythm O2, 2 (2021), pp. 298-303
[11]
E. Yilmaz, K.H. Akay.
The efficacy of colchicine on carotid intima-media thickness: A prospective comparative study.
J Stroke Cerebrovasc Dis, 30 (2021),
[12]
H. Okawa, A. Yamawaki-Ogata, Y. Narita, H. Munakata, R. Hashizume, A. Usui.
P3112 The oral administration of colchicine prevents the progression of aortic aneurysm.
[13]
P. Kelly, C. Weimar, R. Lemmens, S. Murphy, F. Purroy, A. Arsovska, et al.
Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - Study protocol for a randomised controlled trial.
Eur Stroke J, 6 (2021), pp. 222-228
[14]
F.L.J. Visseren, F. Mach, Y.M. Smulders, D. Carballo, K.C. Koskinas, M. Bäck, et al.
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Eur Heart J, 42 (2021), pp. 3227-3337
Copyright © 2022. Sociedad Española de Neurología
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.nrleng.2020.03.004
No mostrar más